Table 1.
Patients' characteristics and demographic data.
| Characteristics | N = 85 |
|---|---|
| Age (years), median (range) | 63 (32–86) |
| Gender, n (%) | |
| Male | 33 (38.8) |
| Female | 52 (61.2) |
| Smoking status, n (%) | |
| Never-smokers | 58 (68.2) |
| Former or current-smokers | 27 (31.8) |
| ECOG PS, n (%) | |
| 0–1 | 77 (90.1) |
| 2–3 | 8 (9.9) |
| Stage, n (%) | |
| Post-operation recurrence | 15 (17.6) |
| Stage 4A | 32 (37.6) |
| Stage 4B | 38 (44.8) |
| Brain metastasis at baseline, n (%) | |
| Yes | 27 (31.8) |
| No | 58 (68.2) |
| Baseline EGFR mutation status, n (%) | |
| Exon 19 deletion# | 61 (71.8) |
| Exon 21 L858R& | 24 (28.2) |
| PD-L1 expression level, n (%) | |
| Negative | 36 (42.4) |
| 1–49% | 27 (31.8) |
| ≧50% | 8 (9.4) |
| Unknown | 14 (16.4) |
| Treatment response | |
| Complete response, n (%) | 1 (1.3) |
| Partial response, n (%) | 59 (77.6) |
| Stable disease, n (%) | 9 (11.9) |
| Disease progression, n (%) | 7 (9.2) |
| Could not be evaluated, n | 9 |
| Objective response rate | 78.9% |
| Disease control rate | 90.8% |
ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; PD-L1, Programmed death-ligand 1.
#1 Exon 19 deletion + Exon 20 insertion; &1 Exon 21 L858R + T790M.